Good day, ladies and gentlemen, and welcome to the Societal CDMO second quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a Q&A session, and instructions will follow at that time. As a reminder, this conference may be recorded. I would now like to hand the conference over to Stephanie Diaz of Societal's Investors Relations Group. Please go ahead. Thank you. Hello, and thank you for joining us. On today's call, we have David Enloe, President and Chief Executive Officer, and Ryan Lake, Chief Financial Officer. Today, we will be providing an overview of Societal's contract development and manufacturing business, including updates on corporate activities and financial results for the quarter and six months ended June 30, 2023. After our prepared remarks, we will welcome your questions. Before we begin, I'd like to caution that comments made during this conference call today, August 14, 2023 will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, concerning the current beliefs of the Company, which involve a number of assumptions, risks and uncertainties. Actual results could differ from these statements, and the Company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the Company's filings with the Securities and Exchange Commission concerning these and other matters. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at societalcdmo.com. With that, I will turn the call over to David Enloe, Societal's President and Chief Executive Officer. Thank you, Stephanie, and thank you to everyone participating today via webcast. The second quarter was a very busy and productive time at Societal CDMO. Despite the financing challenges faced by many of our customers, we continue to attract new business as well as expand work with our existing customers. We are actively onboarding the new business won during the first half, and we are pleased with our progress in these efforts. Additionally, we are pleased to have seen an increase in orders for verapamil, a drug we own outright from our partner, Teva, thus validating the long-term durability of this important part of our product portfolio. Subsequent to quarter end, we achieved two important objectives. First, we recently announced that the company had successfully secured a Schedule I controlled substance manufacturing license from the Drug Enforcement Administration that will allow us to expand our work beyond Schedule II products to manufacture for the growing psychedelic drug market. Subsequent to quarter end, we successfully restructured our debt and certain covenants with our creditors to provide additional financial flexibility to the company during this time of market uncertainty. I will provide a more detailed review of all of our Q2 2023 achievements following an overview of our financial results for the quarter ended June 30, 2023. I'll turn the call over to Ryan. Thank you, David. Good afternoon, everyone. Before I begin, in addition to the brief financial overview I'll provide on the call today, additional details on our financial results for the second quarter and six months ended June 30, 2023, are included in our press release issued prior to this call and in our Form 10-Q, which is on file with the SEC. I will now begin with results for the second quarter. Revenues for the quarter ended June 30, 2023, were $21.8 million, compared to $23.2 million for the comparable 2022 period. The decrease of $1.4 million was primarily driven by a decrease in revenue from the company's largest commercial customer, Teva, due to a scheduled shutdown of our packaging line to implement the upgrades required to comply with the new serialization and aggregation compliance standards. In addition, the new manufacturing revenue associated with the then new customer, InfectoPharm's' inventory build during Q2 2022, was greater than the normalized quarterly revenue recorded in Q2 2023. These reductions in revenue were partially offset by increased pre-commercial development revenues from our clinical trial materials and technology transfer projects. It is important to note that we expect the delayed Teva orders to recover in the short term, supported by the continued pull-through in demand resulting from market share gains against the sole competitor for the Verapamil SR products. Cost of sales for the quarter ended June 30th, 2023, was $17.3 million, compared to $17.5 million for the comparable period of 2022. The decrease of $0.2 million was primarily due to lower commercial manufacturing revenue based on the timing of the serialization and aggregation compliance project, offset by higher fixed costs, primarily to support the newly installed aseptic fill-finish line that has expanded our capabilities. Selling, general, and administrative expenses for the second quarter of 2023 of $5.3 million was consistent with the comparable prior year period of $5.2 million. Interest expense was $2.3 million for the three months ended June 30, 2023, a decrease compared to $3.4 million for the comparable period of 2022. The decrease of $1.1 million was primarily due to a significantly reduced amount of aggregate principal and lower interest rates under the company's refinanced debt as compared to the borrowings outstanding during the period ended June 30, 2022. For the quarter ended June 30th, 2023, the company recorded a net loss of $3.2 million, or $0.04 per diluted share, as compared to a net loss of $3.1 million, or $0.06 per diluted share for the comparable period of 2022. EBITDA, as adjusted for the period, was $2.8 million, compared to $4 million in the prior year period. I'll now review the results for the six months ending June 30th, 2023. Revenue for the six months ended June 30th, 2023, was $43.3 million, compared to $44.3 million for 2022. The decrease of $1 million in revenue was primarily driven by the decreases in revenues from Teva and InfectoPharm, which were partially offset by an increase in pre-commercial development revenues, as discussed previously. Cost of sales for the six months ended June 30th, 2023, was $36.6 million, compared to $33.6 million in 2022. The cost of sales increase of $3 million was primarily due to mix of revenues and related fixed cost absorption, including increased costs associated with the new aseptic fill-finish line that has expanded our capabilities and increased material costs. Selling, general, and administrative expenses for the six months ended June 30th, 2023, were $9.9 million, compared to $10.9 million in 2022. The decrease of $1 million was primarily related to lower public company costs and administrative costs than the prior year. Interest expense was $4.4 million and $6.8 million for the first six months of 2023 and 2022, respectively. The decrease of $2.4 million was primarily due to a significantly reduced amount of aggregate principal and lower interest rates under the company's refinanced debt as compared to the borrowings outstanding during the period ended June 30, 2022. For the six months ended June 30, 2023, Societal reported a net loss of $7.9 million, or $0.09 per diluted share, compared to a net loss of $7.4 million, or $0.13 per diluted share for 2022. EBITDA as adjusted for the six months was $3.4 million, compared to $6.8 million in the prior year period. The $3.4 million decrease in EBITDA is primarily due to a mix of revenue and related fixed cost absorption, offset by reduced selling, general, and administrative costs. This concludes my financial overview. For those interested in reviewing our non-GAAP reconciliations, please refer to our Form 8-K filing or the press release issued today. I'll now turn the call back over to David for an update on operations and achievements during the period. Thanks, Ryan. The second quarter was a highly productive period from an operational perspective. During the quarter, we continued to aggressively pursue and win new business, as well as expand multiple programs with existing customers. In addition to our normal course of business, the company also successfully executed a scheduled maintenance shutdown, as well as an upgrade of our packaging line that was required to make it compliant with new serialization and aggregation standards. Finally, the company recently secured a Schedule I controlled substance manufacturing license from the Drug Enforcement Administration that'll allow us to expand our work beyond Schedule II products to manufacture for the growing psychedelic drug market. Yet, the period was not without challenges. As Ryan reported, we recorded a decline versus Q2 2022 revenues due to a short-term delay in 2023 Teva revenue as a result of the scheduled packaging line shutdown, as well as a revenue delta created by the Q2 2022 InfectoPharm inventory build. Both of these decreases were largely offset by an increase in pre-commercial development revenues, and we believe the Teva revenues will be recovered prior to year-end. These offsets validate our revenue diversification strategy that has been our core focus for the past couple of years. More an issue than these typical variances is the fact that our customers continue to face an unfavorable financing environment. During the first half of the year, several projects were delayed or placed on hold by customers, primarily as a result of either funding challenges or overall cash preservation efforts by those customers. While a certain amount of project attrition is normal in the CDMO business, we are seeing higher rates than in the past that can be directly attributed to the current financing environment. Despite these hurdles, at this time, we do not believe that our top-line year-end revenue guidance will be affected. We do believe that our EBITDA guidance requires revision. We had previously guided to a 2023 full-year EBITDA of between $15 million and $18 million. Today, we are revising our 2023 EBITDA guidance to between $12 million and $15 million. It is important to emphasize that our operations and business fundamentals remain solid at Societal CDMO. This shift in guidance can be attributed to the financing hardships being faced by many companies in the biotech and life science sectors, and we continue to believe that it will be temporary. At the time that our customers secure the needed funding, Societal CDMO will have the talent, the capabilities, and capacity in place and be ready to execute for our clients. While we remain confident that the current financing environment will soon correct, the company has taken proactive steps to fortify our balance sheet today. To this end, the company recently renegotiated our debt structure and certain covenants with our creditors to provide us with additional breathing room as we wait out the current market. Specifically, among other benefits, the new terms defer previous mandatory payments, reduce certain payments, and lower certain minimum liquidity and fixed- charge coverage ratios. This restructuring, which was completed last week, drove our decision to reschedule our earnings announcement. We are very pleased with the outcome of this effort and the additional financial flexibility secured. I would now like to provide a bit more color on our achievements for the quarter. During the second quarter, we signed new business and expanded scope of work agreements for 19 existing programs. During the period, we also expanded both our business development leadership and our sales team, and we are encouraged by the progress we are seeing out of the gate. While the majority of our customers require that we do not disclose our partnerships in order to protect their competitive strategies, we are able to highlight a few new programs signed during the period, including a new project with Xequel Bio, Inc. Through this project, Societal will provide CDMO services to support the ongoing clinical development of a patented new chemical entity based on its ACT-1 platform. The agreement spans a range of our offerings, including process development and clinical trial services, culminating in cGMP manufacturing of the compound and placebo for upcoming Phase II clinical trials of Granexin, which is an ACT-1 ophthalmic solution. INEXION is a sterile, preservative-free ophthalmic solution containing ACT-1 peptide that is currently being evaluated by Xequel for the potential treatment of persistent corneal epithelial defects. During the period, we were also selected by Atossa Therapeutics to provide a range of clinical trial services offerings focused on Atossa's proprietary selective estrogen receptor modulator, or SERM, Z-endoxifen. The agreement spans a range of activities, including analytical method transfer, development and validation, cleaning verification method validation, manufacturing of multiple R&D engineering batches, and stability testing of the R&D engineering batches. The company also signed a Master Services Agreement with CivicaScript. This agreement covers an initial project supporting tech transfer of a generic drug candidate that is moving through development and registration efforts, with the potential to expand to include support of additional CivicaScript programs. Finally, subsequent to the quarter- end, Societal won a new project with Spinnaker Biosciences, Inc. to execute CDMO services supporting the clinical development of a novel therapeutic candidate. The activities to be conducted under this agreement include analytical method transfer and qualification, aseptic process development, manufacture of a prototype batch of the therapeutic, cGMP filling of the resultant sterile powder into vials, and stability testing of the therapeutic candidate to be used in a planned Phase I/II study. As I hope is evident, the scope of these projects span early-stage process development to cGMP manufacturing to fill-finish. We believe this broad range of services highlights a growing customer recognition of Societal CDMO as a start-to-finish partner. We continue to expand our capabilities in an effort to address new and growing markets. The company recently announced that it has taken another step to expand our services by securing a license to manufacture in support of psychedelic drug development. This strategic expansion is a natural fit for the company based on our decades of experience in manufacturing and handling controlled substances. We believe this unique experience positions Societal well to address the emerging psychedelic therapy sector, as well as the growing number of ongoing and planned clinical trials in this area. The company recently announced that it has completed key regulatory requirements and received a U.S. Drug Enforcement Administration approval to add certain Schedule I psychedelic compounds to our controlled substance manufacturing registration. These compounds expand upon the Schedule II manufacturing registration that we have held with the DEA for over 20 years. Importantly, Societal is now able to expand its capabilities into the psychedelic drug development market without committing any additional capital investment. We are currently in discussions with leading drug manufacturers engaged in the psychedelic area, and we look forward to our work in this new and exciting space. In closing, I would like to again reiterate that the company's operational and business fundamentals remain solid. Over the last year, we have substantially reduced our debt, improved our covenants, and strengthened our balance sheet to support our plans for growth. We continue to work to mitigate the impact of today's financing environment on our business, and to that end, we have expanded both our BD leadership as well as our sales team. This group continues to sign new projects to feed our pipeline, and we are very encouraged by the progress they continue to make. As we look forward to the second half of the year, we have a superb team in place, a strong pipeline of customer projects, and a broad range of capabilities that continues to grow to meet new and expanding areas of demand. In short, we believe our organization is well positioned to weather today's temporary financing headwinds and excel in the markets ahead. This concludes my prepared remarks for today. We can now open up the call for questions. Operator? Thank you. To ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw the question, please press star one one again. One moment while we compile the Q&A roster. Our first question comes from the line of Matt Hewitt with Craig-Hallum Capital. Good afternoon. Congratulations on the progress, and thank you for taking the questions. Maybe, maybe first up, regarding the psychedelic opportunity, how quickly could that translate into some new wins? As you look at that opportunity, is there a handful of players, or do you think it, it's, it could become a rapid growth market with a number of different companies, expanding into that area? Yeah. Hi, Matt, David here. Thanks for the question. You know, the, the space is certainly growing, and it's growing rapidly. There are now something like 90 clinical trials in the U.S. testing various drugs that are characterized and classified as psychedelics, usually around mental health disorders, depression, a lot in PTSD. What we're seeing is, is that there are, there, there's a nice amount of throughput on the API side, but not necessarily on the finished dose side, which is where we come in. I'll say to you that we have active discussions that are. These aren't hypothetical, they're specific projects, and, you know, we're doing everything we can to secure those and, and bring them in-house and, and begin to manufacture and produce. That's great. Then regarding the, the broader pipeline, I'm curious what you're seeing in the market right now. Some of your peers have talked about some shifts that have occurred, maybe focusing more energy, more effort towards later-stage. Obviously, you continue to win business across, you know, early to late stage. I'm just curious what you're seeing from, from your customers. Yeah, I mean, there's, you know, as we talked about just prior, I mean, there certainly remains difficulty by the very small companies with early programs to raise the capital necessary to go ahead, and so we're seeing hesitance there to get started. You know, our efforts span very intentionally across the gamut, if you will, and we remain very active on, as you know, Matt, the tech transfer front. We continue to see activity there as companies are weighing the requirements that they have internally for supply chain control and strength by manufacturing in the U.S. That's a space that we continue to emphasize. You know, I think the rest of it kind of speaks for itself. We're seeing fewer opportunities pop up, but we're doing everything we can to win those, and we've seen some nice success this year so far. Got it. Then maybe one last one, I'll hop back in the queue. A nice pop in gross margins here in the second quarter is somewhat expected, but a little bit better than we had been anticipating. How should we think about gross margins in the back half of the year? Thank you. Thanks, Matt. Hi, Matt. Q2 margins were about 21% and rebounded from Q1, and we expect further improvement in margins in the second half, with expected margins to be in the mid-20% range. That's really driven by mix and type of revenue and related cost absorption, including the increased costs associated with the new aseptic fill-finish line and lyophilization, as we expanded those capabilities and increased material costs. You know, one of the big drivers is related to the increase in revenue, and we have a high degree of confidence in the revenue guidance that we've put forth. You know, year-to-date, we've achieved about $43 million or 45% of our full year guidance and expect the second half to be about 55%, with Q3 probably in the mid-20% range. This is consistent with what we communicated previously with the total year revenue weighted, with about 45% in the first half and 55% in the second half. Importantly, you know, we've now completed the serialization and aggregation compliance. That's behind us, and we're now fulfilling the customer demand that has been backed up. We're seeing a lot of those shipments go out this quarter. Commercial revenue is also, you know, increasing in the second half from the launch of the Otsuka and Viatris products. If you get a chance to look at our investor deck, you'll notice that we have an additional Viatris tech transfer project now, as well as some development projects ongoing with them. We also have now, where we stand in the year, commercial customer orders that are already in-house through nearly the end of the year, which de-risked our revenue forecasts, and it was more of a mix of commercial versus development orders. You know, we still have really good line of sight to our development revenue. I think at the midpoint, it's roughly $22 million. We've already earned 40% of that, you know, we expect to earn 50%, or the next 50% from business that's already signed and in-house. The remaining 10% is from business that, you know, we're planning on executing additional new business and scope changes on the current items that are in the sales funnel. That's great. Thank you very much for that color there. Yeah. Thank you. One moment for our next question, please. It comes from the line of Jacob Johnson from Stephens. Please proceed. Hey, thanks. Good afternoon. Ryan, I appreciate all the color you just gave, so you might have answered some of this, but I just want to make sure I understand it. You guys are talking about some macro challenges, which, which seems like most everybody's talking about this quarter, but you're not really changing your revenue outlook, but your EBITDA outlook is trimmed a bit. Is that dichotomy there related to the mix of business being kind of lower margin business now? Can you just kind of help frame why EBITDA guidance is coming down, revenue unchanged in light of the macro? Yeah. The revision to our EBITDA guidance is a result of the impacts on the shift in mix of revenue and higher fixed costs, primarily in development. So we're projecting less development revenue and more commercial revenue. As a result of the macro funding environment in biotech, the slowdown in new signed business and customer delays and customer attrition that David commented on earlier, that's what's causing that mix shift and the higher fixed costs associated with the development business. Okay, got it. That makes sense. Thank you. Then maybe, David, just on the macro, I'm just kind of curious if you're seeing more of these headwinds at some of the legacy capabilities at Gainesville, or if maybe more of this relates to some of the newer capabilities like fill-finish and lyo? Yeah, that's a good question. It across the board. you know, we see fewer- I mean, the, the level of throughput of activity, if you look at the top of our funnel, our marketing efforts, lead identification, qualification, that's all going very well. quite frankly, ahead of, of where we had targeted with each of those metrics. As decisions to award and advance a program, and as best we understand it, by anyone. I mean, you know, we're not losing the business, it's just not being awarded, period. That is a slowdown that, that runs across formulation type right now. Okay, got it. I'll leave it at 2. Thank you. Appreciate it. Thank you. One moment for our next question, please. Comes from the line of, Max Smock with William Blair. Hey, good afternoon, and thanks for taking our questions. I wanted to follow up on Jacob's question. I'm still just trying to understand why EBITDA margin would step down so materially on the same revenue base here. I guess, Ryan, what's really changed relative to last quarter, and you reaffirmed guidance? Can you walk through the margin profile associated with development revenue versus commercial revenue? I would have assumed that commercial would have been higher margin, so mix shift towards more commercial maybe seemed, I would maybe assume to be positive, but it sounds like that's actually the opposite. It'd be helpful to just get some commentary around that dynamic. Yeah. Again, you know, the Q2 margins improved to 21%. They rebounded from a lower Q1, and, you know, the margin profile and mix in the second half of the year is expected to improve to the mid-20% or low 20% range. You know, between development and commercial, keep in mind the nascency of our development revenue business. We have a greater amount of fixed costs associated with the development business. You know, it's almost a one-for-one impact, the shift in mix of development revenue to EBITDA. If development revenue is down, it's not absorbing those fixed costs, which go directly to the bottom line, versus from a commercial perspective, those fixed costs that we have associated with that business are already absorbed through the business, so it doesn't have as much contributory impact to, to the margins. Got it. Understood. Maybe just looking at the slide deck, I'm looking particularly at slide 15, just trying to confirm what you're factoring in the guidance for attrition in the back half of the year here. I'm having a little bit of trouble, frankly, following slide 15. I was wondering if you could just kind of walk us through what exactly is going on there and what exactly each of these revenue buckets entails, and what your assumptions are, I guess, for the back half of this year. Yeah. Let me just pull that up so that I have it handy as well. I think importantly, what this is showing is that from a development revenue perspective, we already have earned 40%, you know, or $9 million of the total estimated revenue from development revenue. Then the other 50% or the $11 million, which is below the line in terms of the second half revenue, that $11 million is already signed business. What's important about that is there is a risk adjustment included in that number. Really, the remaining go-get is about $1 million-$4 million between basically new business and go-get and change of scope of work with existing customers. What we tried to lay out was a waterfall to show you that you know, although we're, you know, winning new work, we're also experiencing, and David mentioned this during his comments, you know, attrition or delays of committed business already at an extent that we hadn't experienced before, which is certainly, you know, you can almost see the direct impact. That decrease in development revenue is, you know, effectively the decrease that we're experiencing from an EBITDA perspective. That's why we're highlighting that $4 million that's circled on that slide. Got it. Understood. Maybe one last quick one from me. Just any guidance you can give us around expected cash burn this year and ending cash balance as we head into 2024? Yeah. We ended Q2 with $4.7 million in cash and cash equivalents. You know, we, we have been, and we're continuing to look at ways that we can reduce our, our cash burn while still prioritizing spend on strategic value and growth drivers. From, you know, a cash flow perspective, we, we still expect to be positive cash flow from operations for the full year. We're prioritizing our capital spending needs, and, you know, customers are also continuing to fund capital expenditures as well. On a go-forward basis, our cash burn from principal and interest is expected to be less after the land sale proceeds and pay down of the RBC debt, which is shifted to the first half of next year. After that, we would have, you know, roughly, only $25 million of senior debt outstanding. You know, we also expect increased profitability from our verapamil franchise as we renegotiate those agreements at the end of 2024 as well. Okay, great. I'll leave it there. Thank you. Thank you. One moment for our next question. It comes from the line of Sean Dodge with RBC Capital Markets. Hey, good afternoon. This is Thomas Keller on for Sean. Thanks for taking the questions. I wanted to come back to Lannett. I believe you said back in May, they had about three to four months of inventory. Any updates you can provide on, on demand front there, or any just general updates on that relationship going forward? The demand for Lannett has been consistent they've continuing to meet their obligations under the agreement, you know, I think, you know, quite honestly, the relationship is, you know, better now that they've emerged from, from bankruptcy. you know, it, it's, you know, Well, technically, all of the verapamil franchise, you know, we see that as a significant asset and one that, you know, we're going to be able to improve upon the economics profit sharing from that as we exit the, the natural agreement that they're currently under, you know, as we enter into those new agreements beginning January 2025. That's helpful. Thank you. Then, and then on the MSA with CivicaScript, I think they've got initial plans for six-10 generics, something like that, I think I saw. How would potential expansion work there beyond that initial program? Is that kind of a competitive process for each, or are you all kind of a, like a default vendor through their potential expansions? Yeah. Hey, Thomas, we're David here. I mean, certainly each project and program is being awarded in and of itself. As we begin the tech transfer work for this one, we expect, like all the other tech transfers, to be very successful and very communicative with them. There's a, quite frankly, a different skill set to succeed in the tech transfer world than earlier stage programs, and for that matter, commercial manufacturing. And we've become very adept at it, have high confidence in our ability to deliver there. We, you know, we've been discussing multiple programs with them, and they are pacing out their programs and projects, you know, consistent with what we describe with the macro market. All right. Thanks, guys. I'll leave it there. Thank you. Thank you. I don't see any further questions in the queue. I will pass it back to David Enloe for closing comments. Great. Thanks. Many thanks to all of our clients, supply chain, and other service providers and partners, and particularly to our excellent Societal team. We look forward to many great achievements in the months ahead. Thank you again for participating today and for your continued support of Societal CDMO. That concludes the program. You may now disconnect.